Literature DB >> 25464905

Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study.

E P A T Gommans1, P Even2, C F M Linssen3, H van Dessel4, E van Haren5, G J de Vries6, A M C Dingemans7, D Kotz8, G G U Rohde9.   

Abstract

BACKGROUND: Infections with non-tuberculous mycobacteria (NTM) represent an increasing problem. Their clinical relevance is still largely unknown as well as predictors for mortality in affected patients. The objective was to describe prevalence and clinical relevance of different NTM and to identify risk factors for mortality.
METHODS: Retrospective cohort study of 124 patients with NTM detection between January 2001 and December 2011. Clinical characteristics like symptoms and radiological appearance were assessed at presentation. The primary outcome was all cause mortality during the follow-up period. Univariate and multivariate survival analyses using Cox proportional hazard models were employed for statistical analysis.
RESULTS: Over the study period, the frequency of NTM isolation varied from 4 to 12 patients per year. Twenty-nine out of 124 patients (23%) had a clinically relevant infection, according to the criteria of the American Thoracic Society (ATS). Mycobacterium avium was isolated most frequently, but Mycobacterium kansasii, Mycobacterium malmoense and Mycobacterium xenopi had the highest clinical relevance. Symptoms were mostly diverse and non-specific. On radiology, cavities were observed more frequently than a nodular-bronchiectatic variant or consolidation. In 75% of all patients, follow up time was more than two years. Median survival was 6.5 years (95%CI = 2.7-10.3). Factors significantly influencing survival time were haemoptysis (HR = 0.2, 95%CI = 0.1-0.6) and a consolidation on imaging (HR = 5.1, 95%CI 1.4-18.2).
CONCLUSIONS: The presentation of an infection with NTM can be diverse and depends mainly on the causative NTM pathogen. The most important predictor for increased mortality is the radiological appearance of a consolidation.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Infection; Mycobacterium avium; NTM; Non-tuberculous mycobacteria

Mesh:

Substances:

Year:  2014        PMID: 25464905     DOI: 10.1016/j.rmed.2014.10.013

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  16 in total

1.  Mortality among patients with pulmonary non-tuberculous mycobacteria disease.

Authors:  M Fleshner; K N Olivier; P A Shaw; J Adjemian; S Strollo; R J Claypool; L Folio; A Zelazny; S M Holland; D R Prevots
Journal:  Int J Tuberc Lung Dis       Date:  2016-05       Impact factor: 2.373

2.  Whole-Blood Gene Expression in Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Steven A Cowman; Joseph Jacob; David M Hansell; Peter Kelleher; Robert Wilson; William O C Cookson; Miriam F Moffatt; Michael R Loebinger
Journal:  Am J Respir Cell Mol Biol       Date:  2018-04       Impact factor: 6.914

Review 3.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

4.  Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Eur Respir J       Date:  2020-07-07       Impact factor: 16.671

5.  Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Authors:  Charles L Daley; Jonathan M Iaccarino; Christoph Lange; Emmanuelle Cambau; Richard J Wallace; Claire Andrejak; Erik C Böttger; Jan Brozek; David E Griffith; Lorenzo Guglielmetti; Gwen A Huitt; Shandra L Knight; Philip Leitman; Theodore K Marras; Kenneth N Olivier; Miguel Santin; Jason E Stout; Enrico Tortoli; Jakko van Ingen; Dirk Wagner; Kevin L Winthrop
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

6.  Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens.

Authors:  Seong Mi Moon; Hye Yun Park; Kyeongman Jeon; Su-Young Kim; Myung Jin Chung; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Sung Jae Shin; Won-Jung Koh
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

7.  Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria.

Authors:  H Kotilainen; V Valtonen; P Tukiainen; T Poussa; J Eskola; A Järvinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-09       Impact factor: 3.267

Review 8.  Pulmonary non-tuberculous mycobacterial infections: current state and future management.

Authors:  Kai Ling Chin; Maria E Sarmiento; Nadine Alvarez-Cabrera; Mohd Nor Norazmi; Armando Acosta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-18       Impact factor: 3.267

9.  Nontuberculous Mycobacterial Infections in a French Hospital: A 12-Year Retrospective Study.

Authors:  Peggy Blanc; Hervé Dutronc; Olivia Peuchant; Frédéric-Antoine Dauchy; Charles Cazanave; Didier Neau; Gaëtane Wirth; Jean-Luc Pellegrin; Philippe Morlat; Patrick Mercié; José-Manuel Tunon-de-Lara; Marie-Sylvie Doutre; Philippe Pélissier; Michel Dupon
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

Review 10.  Non-tuberculous mycobacterial lung disease: a brief review focusing on radiological findings.

Authors:  Laura Raniere Borges Dos Anjos; Poliana Lopes Parreira; Pedro Paulo Teixeira Silva Torres; André Kipnis; Ana Paula Junqueira-Kipnis; Marcelo Fouad Rabahi
Journal:  Rev Soc Bras Med Trop       Date:  2020-09-11       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.